{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:33:45Z","timestamp":1777534425157,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.pbb.2022.173405","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T09:34:09Z","timestamp":1652607249000},"page":"173405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An analog of [d-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress-induced reinstatement of extinguished morphine conditioned place preference"],"prefix":"10.1016","volume":"217","author":[{"given":"Ariana C.","family":"Brice-Tutt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shainnel O.","family":"Eans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Yakovlev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane V.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay P.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1208\/s12248-009-9105-4","article-title":"Peptide kappa opioid receptor ligands: potential for drug development","volume":"11","author":"Aldrich","year":"2009","journal-title":"AAPS J."},{"issue":"43","key":"10.1016\/j.pbb.2022.173405_bb0010","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.0910180106","article-title":"Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action","volume":"106","author":"Aldrich","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cmdc.201100113","article-title":"Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208","volume":"6","author":"Aldrich","year":"2011","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.pbb.2022.173405_bb0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/np300697k","article-title":"The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior","volume":"76","author":"Aldrich","year":"2013","journal-title":"J. Nat. Prod."},{"issue":"13","key":"10.1016\/j.pbb.2022.173405_bb0025","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1111\/bph.12664","article-title":"Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour","volume":"171","author":"Aldrich","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0149-7634(94)00021-R","article-title":"Conditioned place preference using opiate and stimulant drugs: a meta-analysis","volume":"19","author":"Bardo","year":"1995","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(02)02274-4","article-title":"Sex-related differences in mechanical nociception and antinociception produced by \u03bc-and \u03ba-opioid receptor agonists in rats","volume":"452","author":"Barrett","year":"2002","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173405_bb0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.peptides.2018.01.011","article-title":"Endogenous opiates and behavior: 2016","volume":"101","author":"Bodnar","year":"2018","journal-title":"Peptides"},{"issue":"17","key":"10.1016\/j.pbb.2022.173405_bb0055","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3390\/molecules25173999","article-title":"Phenylalanine stereoisomers of CJ-15,208 and [D-Trp]CJ-15,208 exhibit distinctly different opioid activity profiles","volume":"25","author":"Brice-Tutt","year":"2020","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.pbb.2022.173405_bb0060","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1111\/bph.15165","article-title":"Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour","volume":"177","author":"Brice-Tutt","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pbb.2022.173405_bb0065","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of \u03ba opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2022.173405_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2005.09.013","article-title":"Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model","volume":"524","author":"Carroll","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173405_bb0075","series-title":"Annual Surveillance Report of Drug-related Risks and Outcomes\u2014United States Surveillance Special Report","volume":"1","author":"CDC","year":"2019"},{"key":"10.1016\/j.pbb.2022.173405_bb0080","doi-asserted-by":"crossref","first-page":"7620860","DOI":"10.1155\/2016\/7620860","article-title":"Predictors of relapse after inpatient opioid detoxification during 1-year follow-up","volume":"2016","author":"Chalana","year":"2016","journal-title":"J. Addict."},{"issue":"4","key":"10.1016\/j.pbb.2022.173405_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.112.083337","article-title":"Dynorphin\u2013still an extraordinarily potent opioid peptide","volume":"83","author":"Chavkin","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173405_bb0090","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fphar.2019.00678","article-title":"Characterization of sigma 1 receptor antagonist CM-304 and its analog, AZ-66: novel therapeutics against allodynia and induced pain","volume":"10","author":"Cirino","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bph.12132","article-title":"The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting \u03ba opioid receptor antagonism in the CNS after oral administration","volume":"169","author":"Eans","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00508810","article-title":"Quantitative assessment of tolerance to and dependence on morphine in mice","volume":"297","author":"Fernandes","year":"1977","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acschemneuro.0c00086","article-title":"Design, synthesis, and characterization of the macrocyclic tetrapeptide","volume":"11","author":"Ferracane","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.111.185108","article-title":"Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for \u03ba-opioid receptors","volume":"339","author":"Grimwood","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173405_bb0115","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999-2017","volume":"329","author":"Hedegaard","year":"2018","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.pbb.2022.173405_bb0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","author":"Jacobson","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.pbb.2022.173405_bb0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review","volume":"101","author":"Johansson","year":"2006","journal-title":"Addiction"},{"issue":"15","key":"10.1016\/j.pbb.2022.173405_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S0024-3205(97)00074-X","article-title":"Role of noradrenergic functions in the modification of naloxone-precipitated withdrawal jumping in morphine-dependent mice by diabetes","volume":"60","author":"Kamei","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2022.173405_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","article-title":"Dynorphin\/Kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction","volume":"136","author":"Karkhanis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173405_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2015.01.008","article-title":"The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats","volume":"283","author":"Kelsey","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"15","key":"10.1016\/j.pbb.2022.173405_bb0150","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.pbb.2022.173405_bb0155","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database SystRev"},{"issue":"7","key":"10.1016\/j.pbb.2022.173405_bb0160","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0165","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(24)38137-6","article-title":"Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity","volume":"289","author":"McLaughlin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression?","volume":"25","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.pbb.2022.173405_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database SystRev"},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0180","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1213\/ANE.0000000000001683","article-title":"Trends in tramadol: pharmacology, metabolism, and misuse","volume":"124","author":"Miotto","year":"2017","journal-title":"Anesth. Analg."},{"issue":"5","key":"10.1016\/j.pbb.2022.173405_bb0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3949\/ccjm.84a.16091","article-title":"Use and misuse of opioid agonists in opioid addiction","volume":"84","author":"Modesto-Lowe","year":"2017","journal-title":"Cleve. Clin. J. Med."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0190","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0022-3565(25)12304-5","article-title":"Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay","volume":"276","author":"Mogil","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00213-009-1770-6","article-title":"Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats","volume":"210","author":"Negus","year":"2010","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2022.173405_bb0200","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF02245939","article-title":"The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-dawley rats","volume":"118","author":"Nylander","year":"1995","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pbb.2022.173405_bb0205","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.mayocp.2019.03.029","article-title":"Medication-assisted treatment for opioid-use disorder","volume":"94","author":"Oesterle","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00213-005-2259-6","article-title":"Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL\/6 and DBA\/2 inbred strains","volume":"181","author":"Orsini","year":"2005","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2022.173405_bb0215","first-page":"735","article-title":"Behavioral pharmacology of novel kappa opioid receptor antagonists in rats","volume":"22","author":"Page","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2022.173405_bb0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2019.05.026","article-title":"Stress, craving and mood as predictors of early dropout from opioid agonist therapy","volume":"202","author":"Panlilio","year":"2019","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.pbb.2022.173405_bb0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/npp.2017.205","article-title":"Repeated Administration of Opra Kappa (LY2456302), a novel, short-acting, selective KOP-r antagonist, in persons with and without cocaine dependence","volume":"43","author":"Reed","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173405_bb0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1208\/s12248-010-9191-3","article-title":"Identification of two novel, potent, low-liability antinociceptive compounds from the direct in vivo screening of a large mixture-based combinatorial library","volume":"12","author":"Reilley","year":"2010","journal-title":"AAPS J."},{"issue":"38","key":"10.1016\/j.pbb.2022.173405_bb0235","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.tetlet.2010.07.086","article-title":"Synthesis of CJ-15,208, a novel \u03ba-opioid receptor antagonist","volume":"51","author":"Ross","year":"2010","journal-title":"Tetrahedron Lett."},{"issue":"4b","key":"10.1016\/j.pbb.2022.173405_bb0240","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2011.01544.x","article-title":"Novel opioid cyclic tetrapeptides: trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting \u03ba opioid receptor antagonism","volume":"165","author":"Ross","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173405_bb0245","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health","author":"SAMHSA","year":"2019"},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0250","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/npp.2010.67","article-title":"Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin\/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms","volume":"35","author":"Schindler","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"49","key":"10.1016\/j.pbb.2022.173405_bb0255","doi-asserted-by":"crossref","first-page":"19384","DOI":"10.1523\/JNEUROSCI.1979-13.2013","article-title":"Long-term antagonism of \u03ba opioid receptors prevents escalation of and increased motivation for heroin intake","volume":"33","author":"Schlosburg","year":"2013","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.pbb.2022.173405_bb0260","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMc1610830","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pbb.2022.173405_bb0265","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/adb.12133","article-title":"A role for kappa-, but not mu-opioid, receptor activation in acute food deprivation-induced reinstatement of heroin seeking in rats","volume":"20","author":"Sedki","year":"2015","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.pbb.2022.173405_bb0270","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0091-3057(92)90382-P","article-title":"Effect of stress on oral morphine and fentanyl self-administration in rats","volume":"41","author":"Shaham","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0275","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1523\/JNEUROSCI.22-09-03663.2002","article-title":"Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal","volume":"22","author":"Shaw-Lutchman","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173405_bb0280","first-page":"563","article-title":"Differential effects of mu and kappa opioid systems on motivational processes","volume":"75","author":"Shippenberg","year":"1986","journal-title":"NIDA Res. Monogr."},{"issue":"7","key":"10.1016\/j.pbb.2022.173405_bb0285","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.pbb.2022.173405_bb0290","first-page":"176","article-title":"Lapse and relapse following inpatient treatment of opiate dependence","volume":"103","author":"Smyth","year":"2010","journal-title":"Ir. Med. J."},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-010-1844-5","article-title":"Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration","volume":"210","author":"Sperling","year":"2010","journal-title":"Psychopharmacology"},{"issue":"15","key":"10.1016\/j.pbb.2022.173405_bb0300","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/bph.13854","article-title":"Selective \u03ba receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice","volume":"174","author":"Spetea","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173405_bb0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jnr.24704","article-title":"Sex differences in kappa opioid receptor antinociception is influenced by the number of X chromosomes in mouse","volume":"100","author":"Taylor","year":"2022","journal-title":"J. Neurosci. Res."},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0310","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/npp.2013.76","article-title":"Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion","volume":"38","author":"Tejeda","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2022.173405_bb0315","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pbb.2022.173405_bb0320","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0006-2952(01)00761-4","article-title":"Morphine-6\u03b2-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies","volume":"62","author":"Ulens","year":"2001","journal-title":"Biochem. Pharmacol."},{"issue":"15","key":"10.1016\/j.pbb.2022.173405_bb0325","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00213-017-4647-0","article-title":"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats","volume":"234","author":"Valenza","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173405_bb0330","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse","volume":"210","author":"Wee","year":"2010","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2022.173405_bb0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.102.041889","article-title":"The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics","volume":"304","author":"Wilson","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173405_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108310","article-title":"Lyophilized kratom tea as a therapeutic option for opioid dependence","volume":"216","author":"Wilson","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.pbb.2022.173405_bb0350","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10571-020-01034-7","article-title":"Kratom alkaloids, natural and semi-synthetic, show less physical dependence and ameliorate opioid withdrawal","volume":"41","author":"Wilson","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2022.173405_bb0355","series-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","article-title":"Opioids, analgesia and pain management","author":"Yaksh","year":"2018"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:26Z","timestamp":1758775406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":69,"alternative-id":["S0091305722000843"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173405","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analog of [d-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress-induced reinstatement of extinguished morphine conditioned place preference","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173405"}}